Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Darzalex Daratumumab Rd for MM Reimburse with clinical criteria and/or conditions Complete
Darzalex Daratumumab BMP for Multiple Myeloma (newly diagnosed) Reimburse with clinical criteria and/or conditions Complete
Darzalex SC daratumumab Multiple myeloma, eligible for autologous stem cell transplant Active
Daurismo Glasdegib Acute Myeloid Leukemia (AML) Do not reimburse Complete
Daxas Roflumilast Chronic obstructive pulmonary disease Do not list Complete
Dayvigo lemborexant Insomnia Do not reimburse Complete
Delstrigo doravirine lamuvidine tenofovir disoproxil fumarate HIV-1 infection Reimburse with clinical criteria and/or conditions Complete
Demylocan decitabine Myelodysplastic Syndromes Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed
Denavir Penciclovir Herpes labialis (cold sores) Do not list Complete
Descovy Emtricitabine /tenofovir alafenamide HIV-1 infection Reimburse with clinical criteria and/or conditions Complete